li001

Clinical trials for bladder cancer

Clinical Trails /

Clinical trials are exploring a range of innovative therapies for bladder cancer, aiming to improve outcomes while preserving the bladder. Intravesical and Targeted Therapies: Oncolytic viruses like cretostimogene grenadenorepvec and EG-70 are designed to selectively kill cancer cells and activate the immune system. Novel drug delivery systems, such as TAR-210, release chemotherapy (e.g., erdafitinib) over time […]

Clinical trials for bladder cancer Read More »

RNA-Based Cancer Vaccines: Current Progress and Future Perspectives

Immunotherapy /

RNA-based cancer vaccines are rapidly advancing, showing real clinical impact across multiple cancer types. Personalized mRNA vaccines for melanoma, combined with pembrolizumab, reduced recurrence or death risk by 44% compared to pembrolizumab alone. In pancreatic cancer, mRNA vaccines generated long-lasting T-cell responses in half of patients, persisting up to four years. At the University of

RNA-Based Cancer Vaccines: Current Progress and Future Perspectives Read More »

Expanding Treatment Arsenal: New Approvals for Gastrointestinal and Genitourinary Cancers

Treatment /

Recent approvals in gastrointestinal and genitourinary cancers are expanding treatment options with more precise and effective therapies. Pembrolizumab (Keytruda), a PD-1 checkpoint inhibitor, is now approved for colorectal, gastric, and esophageal cancers, showing durable responses, improved survival, and better quality of life for biomarker-selected patients. Trastuzumab (Herceptin), targeting HER2, benefits patients with HER2-positive gastric and

Expanding Treatment Arsenal: New Approvals for Gastrointestinal and Genitourinary Cancers Read More »

FOTIVDA (Tivozanib): A Novel VEGFR Tyrosine Kinase Inhibitor for Advanced Renal Cell Carcinoma

Drug Approvals /

FOTIVDA (tivozanib) is an oral targeted therapy for adults with advanced renal cell carcinoma who have not responded to two or more prior systemic treatments. As a VEGFR tyrosine kinase inhibitor, it blocks VEGFR-1, -2, and -3, disrupting angiogenesis and depriving tumors of the blood supply needed for growth and progression. Treatment is given once

FOTIVDA (Tivozanib): A Novel VEGFR Tyrosine Kinase Inhibitor for Advanced Renal Cell Carcinoma Read More »

Gene therapy for cancer treatment: past, present and future

Precision Medicine /

Gene therapy has become a promising cancer treatment by using the body’s genetic machinery to fight tumors, marking a major advance in personalized medicine. Initially, gene therapy in the late 20th century focused on delivering therapeutic genes via viral vectors, replacing defective tumor-suppressor genes like p53 or introducing “suicide genes” to make cancer cells drug-sensitive.

Gene therapy for cancer treatment: past, present and future Read More »

Innovative treatment options for colorectal cancer

Technology Innovation /

Immunotherapy Checkpoint Inhibitors: Block proteins preventing immune system cancer attack, particularly effective for specific genetic features: MSI-H and dMMR Tumors: High mutation burden makes them immune-visible. Approved treatments include pembrolizumab (Keytruda), nivolumab (Opdivo), and nivolumab plus ipilimumab (Yervoy) for advanced colorectal cancer. The combination significantly improves progression-free survival versus single agents. Adoptive Cell Therapy: Extracts patient immune cells,

Innovative treatment options for colorectal cancer Read More »

Innovative Treatment Techniques in Cancer: A Glimpse into the Future of Oncology

Technology Innovation /

Immunotherapy and Cell-Based Therapies: 1. CAR-T Cell Therapy: Genetically modifies patients’ T-cells to recognize and attack specific cancer cells, then reinfuses them. Shows remarkable success in blood cancers like leukemia, lymphoma, and multiple myeloma. 2. Personalized Cancer Vaccines: Use mRNA technology (similar to COVID-19 vaccines) to create custom vaccines targeting individual tumor proteins, helping the immune system

Innovative Treatment Techniques in Cancer: A Glimpse into the Future of Oncology Read More »

Integrating Immunotherapy In Treatment for Patients With Triple-Negative Breast Cancer

Immunotherapy /

Triple-negative breast cancer (TNBC) is an aggressive form lacking estrogen, progesterone, and HER2 receptors, which historically limited treatment to chemotherapy. Recent advances in immunotherapy have transformed care, especially because TNBC tumors are often more immunogenic, with higher levels of tumor-infiltrating lymphocytes and PD-L1 expression that make them responsive to immune-targeting treatments. Checkpoint inhibitors are the

Integrating Immunotherapy In Treatment for Patients With Triple-Negative Breast Cancer Read More »

Magnetodrone Technology: Precision-Guided Cancer Therapy at the Microscale

Technology Innovation /

Magnetodrone technology is a new, precision-guided cancer therapy that uses microscopic, self-propelled bacteria to deliver drugs directly into solid tumors. This innovative approach aims to overcome a major limitation of traditional treatments: the inability of drugs to effectively reach and penetrate the entire volume of a tumor. How Magnetodrones Work The Magnetodrones: These are non-pathogenic,

Magnetodrone Technology: Precision-Guided Cancer Therapy at the Microscale Read More »

Mitomycin Intravesical Solution: A New Standard for Recurrent Low-Grade Bladder Cancer

Molecular Oncology /

Recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) has traditionally required repeated TURBT surgeries due to high recurrence rates, placing significant physical and emotional burdens on patients. Elderly patients, in particular, face frequent procedures under anesthesia and ongoing surveillance, which can severely impact quality of life. FDA-approved Zusduri (mitomycin intravesical solution) now provides the first non-surgical

Mitomycin Intravesical Solution: A New Standard for Recurrent Low-Grade Bladder Cancer Read More »